Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase
- 16 February 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (4), 1889-1903
- https://doi.org/10.1021/acs.jmedchem.0c01955
Abstract
The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies have validated this enzyme as an attractive drug target in chronic inflammatory diseases. Despite several attempts, no LTA4H inhibitor has reached the market, yet. Herein, we disclose the discovery and preclinical profile of LYS006, a highly potent and selective LTA4H inhibitor. A focused fragment screen identified hits that could be cocrystallized with LTA4H and inspired a fragment merging. Further optimization led to chiral amino acids and ultimately to LYS006, a picomolar LTA4H inhibitor with exquisite whole blood potency and long-lasting pharmacodynamic effects. Due to its high selectivity and its ability to fully suppress LTB4 generation at low exposures in vivo, LYS006 has the potential for a best-in-class LTA4H inhibitor and is currently investigated in phase II clinical trials in inflammatory acne, hidradenitis suppurativa, ulcerative colitis, and NASH.Funding Information
- Novartis Institutes for Biomedical Research Inc.
This publication has 33 references indexed in Scilit:
- CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference DrugsDrug Metabolism and Disposition, 2011
- A Critical Role for LTA 4 H in Limiting Chronic Pulmonary Neutrophilic InflammationScience, 2010
- Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 BiosynthesisJournal of Medicinal Chemistry, 2009
- Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment CrystallographyJournal of Medicinal Chemistry, 2009
- Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediatorsNature Reviews Immunology, 2008
- Anti-Inflammatory and Proresolving Lipid MediatorsAnnual Review Of Pathology-Mechanisms Of Disease, 2008
- LeukotrienesNew England Journal of Medicine, 2007
- Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor ZileutonJournal of Pharmacology and Experimental Therapeutics, 2007
- Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1-7British Journal of Dermatology, 2006
- Neutrophil-derived leukotriene B4 is required for inflammatory arthritisThe Journal of Experimental Medicine, 2006